2018 was another big year for new products released by Peptides International. Of course a number of these were from our select group of distributors, which allows for a broad network and portfolio of offerings, yet the year saw many new products originate from PI’s own labs as well. There were over 130 additions, in total for 2018.
One of the flagship product lines, RGD peptides, was represented by two entries. Named for the Arg-Gly-Asp (RGD) in their sequence, they are a cell attachment site for many proteins and are involved in many cell processes including cell proliferation and differentiation. Many strategies for fighting disease target these RGD-binding integrins because they are easily accessible and inhibited by peptides, peptidomimetics, and monoclonal antibodies.1
Antisera Comes On Strong
The Antisera category has had few additions over the last few years, but 2018 turned out to be a very active year. There were no less than 40 antisera, and these were predominately ELISA kits and diabetes research products. The undiluted antisera are suitable for immunohistochemical use, for application to RIA, or other non-isotopic immunoassay purposes. These antisera are partially characterized by either EIA or ELISA. The following represents just one-tenth of the antisera added this year:
- Glucagon-HS ELISA NYK-88091
- Insulin-ELISA Kit NYK-88060
- Human CRF ELISA NYK-88132
- Leptin (Rat)-ELISA Kit NYK-88050
Cell penetrating peptides have the ability to cross cell membranes and can be conjugated with cargo molecules which can be internalized into a cell with the cargo remaining intact. These peptides have the ability to deliver payloads that can inhibit or interrupt intracellular function. Cell penetrating peptides have really shown increasing interest to drug discovery researchers in the last few years and is growing category at PI as well, with three new products just in the last few months.
- H-[Lys-Leu-Ala-Lys-Leu-Ala-Lys]2-Gly-Phe-Leu-Gly-(Cys-Gln-Thr-Pro-Tyr-Tyr-Met-Asn-Thr-Cys)-OH CAN-3505-PI
- Biotinylated Tat (47-57) TAT-3841-PI
- Tat (47-57) TAT-3768-PI
Since including the recombinant protein category a few years ago – by far our biggest catalog product section, with over 4000 currently available – there have been dozens more added each subsequent year. In 2018 we added over two dozen, with applications ranging from Parkinson’s disease, cancer, and cell adhesion.
- Parkinson Disease Protein 2 Human Recombinant PRO-1840
- Parkinson Disease Protein 7 Mouse Recombinant PRO-2226
- CDH1 Human, HEK PRO-2197
- CDH1 Human, Sf9 PRO-2265
- CDH2 Human PRO-2455
- CUB Domain Containing Protein 1 Human RecombinantPRO-2264
New Categories Added
One important development was adding categorization of catalog products by their applications to disease state research. For example, while it is useful to some end-users to know the categories of products by their types (“What is it?”), many researchers would also want to know their application to their investigations (“What is it for?”). This ongoing project, when completed, should prove especially useful when searching for products on the website.
To date, these are the disease states that products are being tagged with:
It is our hope that this organizational structure will make it even easier to find relevant information and our products when searching pepnet.com.
For a complete list, we invite you to take a look at our New Products Brochure. For the most up-to-date and comprehensive list of products, please visit our online catalog. As usual, we offer discounts on bulk quantities and have custom peptide synthesis services. Contact us today to learn more.
Thank you for your patronage in 2018 and we hope you have a happy New Year!
C.-C. Sun, X.-J. Qu, & Z.-H. Gao, American Journal of Therapeutics, 23, e198 (2016). Abstract retrieved from https://www.ncbi.nlm.nih.gov/pubmed/24621642